



(51) International Patent Classification:

A61K 35/28 (2015.01) A61P 7/00 (2006.01)
C12N 5/077 (2010.01)

(21) International Application Number:

PCT/CN2023/115740

(22) International Filing Date:

30 August 2023 (30.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/374,386 02 September 2022 (02.09.2022) US

(71) Applicant: **MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER** [CN/CN]; 7F., No. 9, Wuquan Rd., Wugu Dist., New Taipei City, Taiwan 248016 (CN).

(72) Inventors: **LIN, Hsiu-Hsia**; 6F., No. 6, Ln. 7, Wuquan Rd., Wugu Dist., New Taipei City, Taiwan 248016 (CN). **LIN, Hung-Jun**; 6F., No. 6, Ln. 7, Wuquan Rd., Wugu Dist., New Taipei City, Taiwan 248016 (CN). **JIANG, Ping-Lun**; 6F., No. 6, Ln. 7, Wuquan Rd., Wugu Dist., New Taipei City, Taiwan 248016 (CN). **HSIEH, Chung-Pin**; 6F., No.

6, Ln. 7, Wuquan Rd., Wugu Dist., New Taipei City, Taiwan 248016 (CN). **KUO, Yi-Chih**; 6F., No. 6, Ln. 7, Wuquan Rd., Wugu Dist., New Taipei City, Taiwan 248016 (CN). **KAO, Chien-Yu**; 6F., No. 6, Ln. 7, Wuquan Rd., Wugu Dist., New Taipei City, Taiwan 248016 (CN).

(74) Agent: **TIE CHI PATENT FIRM**; Rm. 705, 7F, Jialong International Tower, No. 19 Chaoyang Park Road, Chaoyang District, Beijing 100026 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: USE OF COMPOSITION INCLUDING MESENCHYMAL STEM CELLS FOR ALLEVIATING MYELOFIBROSIS




FIG. 4

(57) Abstract: Use of a composition including mesenchymal stem cells in the manufacture of a medicament for alleviating myelofibrosis in a subject is provided.

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*